This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Afsharian, P. Articles by Hassan, M. Search for Related Content PubMed PubMed Citation Articles by Afsharian, P. Articles by Hassan, M.

The Effect of Repeated Administration of Cyclophosphamide on Cytochrome P450 2B in Rats

Authors' Affiliations: ¹ Experimental Cancer Medicine, Clinical Research Center and ² Centrum for Allogeneic Stem Cell Transplantaion, Karolinska University Hospital, Huddinge, Sweden; ³ Department of Research DMPK, AstraZeneca R&D Södertälje, Södertälje, Sweden; and ⁴ Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

Requests for reprints: Moustapha Hassan, Experimental Cancer Medicine, Clinical Research Center, Novum, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden. Phone: 46-8-58583862; Fax: 46-8-58583810; E-mail: Moustapha.Hassan{at}ki.se.

Purpose: The prodrug cyclophosphamide (CPA) is activated by cytochrome P450 (CYP) enzymes. CPA is one of the corner stones in all cancer treatment. We have studied the effect of repeated doses of CPA given at different time intervals on the mRNA, protein levels, and enzyme activity of CYPs in rats.

Experimental Design: Two groups of animals (A-75 and A-150) were treated with four doses of CPA (75 and 150 mg/kg, respectively) at short time intervals (6 h). The third group of animals (B-150) was treated with 150 mg/kg at 24-h intervals. Three animals were killed 30 min after administration, and three animals immediately before the next dose.

Results: CYP2B1 and CYP2B2 mRNAs were significantly induced at 6 h after each dose in group A-75 (maximum of 2100-fold and 60-fold after the third dose, respectively), whereas the mRNA levels measured at 6 h postadministration in group A-150 were 1,490-fold and 36-fold after the second dose. In group B-150, no significant induction of mRNA levels was observed. CYP2B1 and CYP2B2 protein levels also increased with increased mRNAs. Plasma levels of 4-hydroxy-CPA measured at 30 min after dose correlated well with the increase in protein levels.

Conclusion: Up-regulation of CYP2B mRNA, with a concomitant increase in protein expression and activity, were observed after repeated administration of low doses of CPA compared with that found using higher doses, possibly due to toxicity counteracting induction. These results may help in designing more effective dosing schedules for CPA.